Overview

Testosterone in Metastatic Renal Cell Carcinoma Patients

Status:
Completed
Trial end date:
2019-07-30
Target enrollment:
Participant gender:
Summary
Purpose To determine efficacy and safety of Testosterone in male patients with metastatic renal cell carcinoma and fatigue receiving targeted therapy or checkpoint inhibitors.
Phase:
Phase 2
Details
Lead Sponsor:
Kidney Cancer Research Bureau
Treatments:
Methyltestosterone
Sunitinib
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate